GlassScriptPhysician profile
Vito J Bagnato
NPI 1508853219
$4,753.06
in general payments reported to CMS, 2019-2025
23 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,540 · 2020: $201 · 2021: $400 · 2022: $129 · 2023: $278 · 2024: $95.68 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.02 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,117.17 | 2019 | |
| Reshape Lifesciences INC. | $292.60 | 2019-2022 | |
| Ethicon US, LLC | $231.88 | 2019-2023 | Echelon Flex |
| Endo Pharmaceuticals INC. | $194.62 | 2019-2023 | Nascobal |
| Redhill Biopharma INC. | $149.22 | 2020-2021 | |
| Edwards Lifesciences Corporation | $143.20 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $109.15 | 2023-2024 | Dupixent |
| Vertex Pharmaceuticals Incorporated | $64.59 | 2025 | |
| La Jolla Pharmaceutical Company | $57.58 | 2021 | |
| Novo Nordisk INC | $51.92 | 2019-2025 | Wegovy |
| Enterra Medical, INC. | $44.95 | 2023 | |
| Merck Sharp & Dohme LLC | $33.71 | 2020-2024 | Bridion |
| Olympus America INC. | $32.65 | 2023 | Olympus |
| Teleflex LLC | $32.61 | 2021-2023 | Weck |
| Tela Bio, INC. | $31.10 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $30.04 | 2022 | |
| Currax Pharmaceuticals LLC | $27.96 | 2025 | Contrave |
| Heron Therapeutics, INC. | $21.23 | 2023 | Zynrelef |
| Mauna Kea Technologies, INC. | $19.84 | 2021 | |
| Boston Scientific Corporation | $19.00 | 2024 | |
| Covidien LP | $17.58 | 2019 | |
| Lilly USA, LLC | $15.26 | 2024 | Zepbound |
| Standard Bariatrics, INC. | $15.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vito Bagnato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.